New Delhi: Japanese pharmaceutical company Eisai on Monday announced the launch of Leqembi (lecanemab) in India for the treatment of early Alzheimer's disease after procuring marketing authorisation from the Central Drugs Standard Control Organisation (CDSCO). The company said Leqembi is indicated for patients with Mild Cognitive Impairment (MCI) and mild dementia due to early Alzheimer's disease, marking the introduction of the country's first disease-modifying therapy (DMT) for the condition. It works by removing existing amyloid-beta plaques, which are abnormal protein deposits in the brain that trigger inflammation and damage nerve cells over time, contributing to memory loss and other symptoms of Alzheimer's disease. The therapy is approved for use in patients with early-stage Alzheimer's disease, including those with MCI and mild dementia, the company said. "What is promising about LEQEMBI (lecanemab) is its ability to intervene early in the disease process.